Sanofi Bolsters Pipeline with Atopic Dermatitis Win and Genetic Therapy Foray
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.